Fondation Hans Wilsdorf

The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.

Danielle Burger, Rachel Chicheportiche, Judith G. Giri et al. · Journal of Clinical Investigation · 1995 · 162 citations · Full text

Veterinary Medicine, Immunology, Pharmacology +17

Interleukin-1, tumor necrosis factor and their specific inhibitors.

J M Dayer, Douglas C. Burger · PubMed · 1995 · 112 citations

Medicine, Immunology, Pathology +15

Regulatory Effects of Interleukin (IL)-1, Interferon-β, and IL-4 on the Production of IL-1 Receptor Antagonist by Human Adipose Tissue

Cristiana E. Juge-Aubry, Emmanuel Somm, Rachel Chicheportiche et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 106 citations · Full text

Life Sciences, Immunology, Physiology +17

Modulation of Endotoxic Activity of Lipopolysaccharide by High-Density Lipoprotein

Christophe Baumberger, Richard J. Ulevitch, J M Dayer · Pathobiology · 2008 · 97 citations

Life Sciences, Biochemistry, Immunology +10

Tumor Necrosis Factor Soluble Receptor 75: The Principal Receptor Form Released by Human Alveolar Macrophages and Monocytes in the Presence of Interferon γ

Béatrice Galve-de Rochemonteix, Laurent Nicod, Jean‐Michel Dayer · American Journal of Respiratory Cell and Molecular Biology · 1996 · 40 citations

Life Sciences, Cell Biology, Immunology +17